The ALDH1A1 Knockout A2780 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout population in which the ALDH1A1 gene has been disrupted, abolishing enzymatic activity. Derived from the A2780 ovarian cancer line, this heterogeneous loss-of-function model maintains cellular diversity while enabling reliable ALDH1A1 functional studies. The pooled editing strategy avoids clonal artifacts and supports large-scale screening applications.
The A2780 cell line is a widely used model of human ovarian endometrioid adenocarcinoma with wild-type p53 status, established from an untreated patient. This epithelial cancer line is commonly employed for ovarian cancer research, including drug response and stem cell studies, making it a relevant host for ALDH1A1 knockout.
ALDH1A1 encodes a cytosolic aldehyde dehydrogenase that catalyzes retinal oxidation to retinoic acid and detoxifies acetaldehyde. It is transcriptionally regulated by RARs, PPAR??, NRF2, and p53. Retinoic acid activates RAR/RXR heterodimers, inducing target genes such as HOX clusters and CYP26A1. ALDH1A1 interacts with CRABP1 and CRABP2 and functionally cooperates with RAR?? and RXR, while also converting acetaldehyde to acetate. The enzyme maintains intracellular retinoic acid levels governing stem cell self-renewal and differentiation.
In the A2780 ovarian cancer background, where ALDH1A1 is often expressed and associated with cancer stem cell traits and chemoresistance, the polyclonal knockout model provides an ideal platform to dissect ALDH1A1-dependent phenotypes. By eliminating ALDH1 dehydrogenase activity, the cells exhibit impaired retinoic acid synthesis from retinal, leading to disrupted RAR/RXR signaling and altered expression of downstream targets. This perturbation can affect cellular differentiation, reduce stemness, and modulate sensitivity to anticancer agents. The polyclonal format ensures representation of diverse genetic backgrounds, minimizing clonal artifacts and enabling robust comparisons with parental A2780 cells in functional assays.
These polyclonal knockout cells are designed for a wide range of functional studies, including Aldefluor-based ALDH activity measurement, retinoic acid quantification by HPLC, and tumor sphere formation assays to evaluate self-renewal capacity. They support investigations into drug resistance via MTT assays and flow cytometry for stem cell markers, as well as migration studies using wound healing assays. The model is well-suited for high-throughput screening of ALDH1A1 inhibitors, retinoid signaling analyses by RT-qPCR of HOX genes and CYP26A1, and metabolism studies. For technical support, custom product requests, or ordering information, please contact Ascent Research.
